The Ability Pre-operative Serum (Cancer Antigen-125, Fatty Acid Synthase, and Glucose Transporter) to Predict Primary Suboptimal Cytoreduction in Epithelial Ovarian Cancer
DOI:
https://doi.org/10.3889/oamjms.2020.4817Keywords:
Epithelial ovarian cancer, Cancer Antigen-125, Fatty Acid Synthase, Glucose Transporter, Cytoreductive surgeryAbstract
BACKGROUND: The incidence of ovarian cancer ranks 8th in the world, with 295,414 cases and 184,799 death in 2018. Management in ovarian cancer is surgery and chemotherapy. Some studies state that patients who underwent optimal cytoreduction surgery have better survival rates than suboptimal cytoreduction surgery. The pre-operative serum assessed in this study was Cancer Antigen-125 (CA-125), Fatty Acid Synthase (FASN), and Glucose Transporter (GLUT) to predict suboptimal cytoreduction in epithelial ovarian cancer (EOC).
AIM: We aimed to use FASN and GLUT1 as other biomarkers, besides CA-125, to predict suboptimal cytoreduction surgery in epithelial ovarian cancer.
METHODS: This observational-analytic cross-sectional study included 109 women diagnosed with epithelial ovarian cancer (EOC) between 2017 and 2019, who had serum CA-125, FASN, and GLUT measured preoperatively and underwent cytoreductive surgery.
RESULTS: The results of the statistical analysis test in this study obtained p values at CA-125 (p = 0.0001), FASN (p = 0.017), and at GLUT (p = 0.013). While the cutoff point (COP) on CA-125 was 248.55, FASN was 0.445, and GLUT was 0.1980. The value of area under curve (AUC) obtained by the ROC method at CA-125 76.7%, FASN 65.3%, and GLUT 63.8%. The combination of CA-125 and FASN shows AUC value 76.9%, the combination of CA-125 and GLUT shows AUC value 72.2%, and the combination of the three shows AUC value 75.2%.
CONCLUSION: The use of CA-125 as a predictor of cytoreduction surgery is still considered to be the best predictor compared to serum biomarkers in this study.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
World Health Organization. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality, and Prevalence Worldwide in 2012. World Health Organization2012. Available from: http://www.globocan.iarc.fr/Pages/fact_sheets_population.aspx. [Last accessed on 2017 Apr 25].
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492 PMid:30207593
Morgan RJ, Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Behbakht K, Chen LM, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Ovarian Cancer, Including Fallopian Tube Cancer and Primary Peritoneal Cancer; 2015. Available from: http://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. [Last accessed on 2015 Jun 22]. https://doi.org/10.1097/01.cot.0000397191.46574.8b
Prat J. The International Federation of Gynecologists and Obstetricians. New FIGO Ovarian Cancer Staging Guidelines; 2014. Available from: https://www.sgo.org/clinical-practice/guidelines/new-figo-ovarian-cancer-staging-guidelines. [Last accessed on 2017 Jan 01]. https://doi.org/10.1016/j.bpobgyn.2015.03.006
Obeidat B, Latimer J, Crawford R. Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA-125 level. Gynecol Obst Invest. 2004;57(3):153-6. https://doi.org/10.1159/000076236 PMid:14726621
Eltabbakh GH, Mount SL, Beatty B, Simmons-Arnold L, Cooper K, Morgan A. Factors associated with cytoreducibility among women with ovarian carcinoma. Gynecol Oncol. 2004;95(2):377-83. https://doi.org/10.1016/j.ygyno.2004.07.045 PMid:15491760
Rodriguez N, Rauh-Hain JA, Shoni M, Berkowitz RS, Muto MG, Feltmate C, et al. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol. 2012;125(2):362-6. https://doi.org/10.1016/j.ygyno.2012.02.006 PMid:22333992
Martínez-Saíd H, Rincon D, De Oca MM, Ruiz G, Ponce J, López-Graniel C. Predictive factors for irresectability in advanced ovarian cancer. Int J Gynecol Cancer. 2004;14(3):423-30. https://doi.org/10.1111/j.1048-891x.2004.014301.x PMid:15228414
Qayyum A, Coakley FV, Westphalen AC, Hricak H, Okuno WT, Powell B. Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. Gynecol Oncol. 2005;96(2):301-6. https://doi.org/10.1016/j.ygyno.2004.06.054 PMid:15661212
Testa AC, Ludovisi M, Mascilini F, Di Legge A, Malaggese M, Fagotti A, et al. Ultrasound evaluation of intra-abdominal sites of disease to predict likelihood of suboptimal cytoreduction in advanced ovarian cancer: A prospective study. Ultrasound Obstet Gynecol. 2012;39(1):99-105. https://doi.org/10.1002/uog.10100 PMid:21913276
Bristow RE, del Carmen MG, Pannu HK, Cohade C, Zahurak ML, Fishman EK, et al. Clinically occult recurrent ovarian cancer: Patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol. 2003;90(3):519-28. https://doi.org/10.1016/s0090-8258(03)00336-6 PMid:13678719
Tang Z, Chang X, Ye X, Li Y, Cheng H, Cui H. Usefulness of human epididymis protein 4 in predicting cytoreductive surgical outcomes for advanced ovarian tubal and peritoneal carcinoma. Chin J Cancer Res. 2015;27(3):309-17. PMid:26157328
Bottoni P, Scatena R. The role of CA 125 as tumor marker: Biochemical and clinical aspects. Adv Exp Med Biol. 2015;867:229- 44. https://doi.org/10.1007/978-94-017-7215-0_14 PMid:26530369
Komura N, Mabuchi S, Yokoi E, Kozasa K, Kuroda H, Kodama M, et al. Prognostic significance of pretreatment leukocyte alterations in patients with epithelial ovarian cancer. J Obstet Gynaeco Res. 2017;43(S1):102-31.
Budiana IN, Suhatno, Hoesin F, Budiono. Profil ekspresi caspase-3 pada kanker ovarium tipe epitel. Indones J Cancer. 2013;7(3):85-91.
Chudeckaneta AM, Cymbaluk A, Menkiszak JL, Sompolska AM, Tołoczko AI, Rzepka IA. Serum HE4, CA125, YKL-40, bcl- 2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer. J Ovarian Res. 2014;7(62):62. https://doi.org/10.1186/1757-2215-7-62 PMid:25018782
Eo W, Kim HB, Lee YJ, Suh DS, Kim KH, Kim H. Preoperative lymphocyte-monocyte ratio is a predictor of suboptimal cytoreduction in stage III-IV epithelial ovarian cancer. J Cancer. 2016;7(13):1772-9. https://doi.org/10.7150/jca.15724 PMid:27698915
Riedl CC, Akhurst T, Larson S, Stanziale SF, Tuorto S, Bhargava A, et al. 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med. 2007;48(5):771-5. https://doi.org/10.2967/jnumed.106.037291 PMid:17475966
Barron CC, Bilan PJ, Tsakiridis T, Tsiani E. Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment. Metabolism. 2015;65(2):124-39. https://doi.org/10.1016/j.metabol.2015.10.007 PMid:26773935
Adekola K, Rosen ST, Shanmugam M. Glucose transporters in cancer metabolism. Curr Opin Oncol. 2012;24(6):650-4. PMid:22913968
Augustin R. The protein family of glucose transport facilitators: It’s not only about glucose after all. IUBMB life. 2010;62(5):315- 33. https://doi.org/10.1002/iub.315 PMid:20209635
Thorens B, Mueckler M. Glucose transporters in the 21st Century. Am J Physiol Endocrinol Metab. 2010;298(2):E141-E5. PMid:20009031
Calvo MB, Figueroa A, Pulido EG, Campelo RG, Aparicio LA. Potential role of sugar transporters in cancer and their relationship with anticancer therapy. Int J Endocrinol. 2010;2010:205357. https://doi.org/10.1155/2010/205357 PMid:20706540
Cantuaria G, Fagotti A, Ferrandina G, Magalhaes A, Nadji M, Angioli R, et al. GLUT-1 expression in ovarian carcinoma: Association with survival and response to chemotherapy. Cancer. 2001;92(5):1144-50. https://doi.org/10.1002/1097-0142(20010901)92:5<1144::aid-cncr1432>3.0.co;2-t PMid:11571727
Tsukioka M, Matsumoto Y, Noriyuki M, Yoshida C, Nobeyama H, Yoshida H, et al. Expression of glucose transporters in epithelial ovarian carcinoma: Correlation with clinical characteristics and tumor angiogenesis. Oncol Rep. 2007;18(2):361-8. https://doi.org/10.3892/or.18.2.361 PMid:17611657
Semaan A, Munkarah AR, Arabi H, Bandyopadhyay S, Seward S, Kumar S, et al. Expression of GLUT-1 in epithelial ovarian carcinoma: Correlation with tumor cell proliferation, angiogenesis, survival and ability to predict optimal cytoreduction. Gynecol Oncol. 2011;121(1):181-6. https://doi.org/10.1016/j.ygyno.2010.11.019 PMid:21167567
Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11(2):85-95.
PMid:21258394
Ameer F, Scandiuzzi L, Hasnain S, Kalbacher H, Zaidi N. De novo lipogenesis in health and disease. Metabolism. 2014;63(7):895- 902. https://doi.org/10.1016/j.metabol.2014.04.003 PMid:24814684
Ueda SM, Yap KL, Davidson B, Tian Y, Murthy V, Wang TL, et al. Expression of fatty acid synthase depends on NAC1 and is associated with recurrent ovarian serous carcinomas. J Oncol. 2010;2010:285191. https://doi.org/10.1155/2010/285191 PMid:20508725
Cai J, Xu L, Tang H, Yang Q, Yi X, Fang Y, et al. The role of the PTEN/PI3K/Akt pathway on prognosis in epithelial ovarian cancer: A meta-analysis. Oncologist. 2014;19(5):528-35. https://doi.org/10.1634/theoncologist.2013-0333 PMid:24718516
Romanidis K, Nagorni EA, Halkia E, Pitiakoudis M. The role of cytoreductive surgery in advanced ovarian cancer: The general surgeon’s perspective. Management. 2014;7(9):12.
Chang SJ, Hodeib M, Chang J, Bristow RE. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: A meta-analysis. Gynecol Oncol. 2013;130(3):493-8. https://doi.org/10.1016/j.ygyno.2013.05.040 PMid:23747291
Bacalbasa N, Dima S, Balescu I, David L, Brasoveanu V, Popescu I. Results of primary cytoreductive surgery in advanced-stage epithelial ovarian cancer: A single-center experience. Anticancer Res. 2015;35(7):4099-104. https://doi.org/10.1016/j.hpb.2016.03.120 PMid:26124361
Vorgias G, Iavazzo C, Savvopoulos P, Myriokefalitaki E, Katsoulis M, Kalinoglou N, et al. Can the preoperative Ca-125 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? A single institution cohort study. Gynecol Oncol. 2009;112(1):11-5. https://doi.org/10.1016/j.ygyno.2008.09.020 PMid:19119502
Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of gynecologic oncology and american society of clinical oncology clinical practice guideline. Gynecol Oncol. 2016;143(1):3-15. https://doi.org/10.1016/j.ygyno.2016.05.022
Kessous R, Wissing MD, Piedimonte S, Abitbol J, Kogan L, Laskov I, et al. CA‐125 reduction during neoadjuvant chemotherapy is associated with success of cytoreductive surgery and outcome of patients with advanced high-grade ovarian cancer. Acta Obstet Gynecol Scand. 2020;99(7):933- 40. https://doi.org/10.1111/aogs.13814 PMid:31954071
Haridas D, Ponnusamy MP, Chugh S, Lakshmanan I, Seshacharyulu P, Batra SK. MUC16: Molecular analysis and its functional implications in benign and malignant conditions. FASEB J. 2014;28(10):4183-99. https://doi.org/10.1096/fj.14-257352 PMid:25002120
Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7(10):763-77. https://doi.org/10.1038/nrc2222 PMid:17882277
Rysman E, Brusselmans K, Scheys K, Timmermans L, Derua R, Munck S, et al. De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res. 2010;70(20):8117-26. https://doi.org/10.1158/0008-5472.can-09-3871 PMid:20876798
Downloads
Published
How to Cite
License
Copyright (c) 2020 Gatot Nyarumenteng Adhipurnawan Winarno, Yudi Mulyana Hidayat, Setiawan Soetopo, Sofie Rifayani Krisnadi, Maringan Diapari Lumban Tobing, Syahrul Rauf (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
